MedTrace Logo

Investigating the Metabolic and Lipidomic Profiles That Are Associated With Varying Grades of Diabetic Maculopathy and Retinopathy in South Wales

NCT06914778 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 120

Last updated 2025-04-10

No results posted yet for this study

Summary

Diabetes mellitus is a disorder of sugar and fat metabolism which results in damage to the small blood vessels in various organs, this includes the retina - the part of the eye that processes light into a nerve impulse. This leads to damage and blindness via various different mechanisms that are not fully understood.

In this study the objective is to recruit people with diabetes and various stages of diabetic eye disease and measure a large number of different chemicals within the blood that might be associated with damage and dysfunction within the retina. Additionally, it will examine the different bacteria within the gut that might affect disease in the eye via chemicals circulating in the blood. This will require participants to have blood samples taken and to provide urine samples. The blood will be analysed with specialised instruments to identify specific molecules circulating within the blood. Participants will also need to allow researchers to look at their medical records, previous photographs and specialist scans of the back of the eye to grade their diabetic retinopathy. This will allow us to identify potential ways in which these could be targeted for future benefit for people with diabetes to hopefully prevent deterioration of their vision.

Conditions

  • Diabetic Retinopathy (DR)
  • Diabetic Retinopathy Associated With Type 2 Diabetes Mellitus
  • Diabetic Macular Edema (DME)

Interventions

OTHER

Blood draw for the laboratory assessment

Blood plasma collection for for lipidomic and metabolomic analysis

OTHER

Urine sample

Urine sampling for aqueous metabolomics

Sponsors & Collaborators

  • University of Aberdeen

    collaborator OTHER

  • Hywel Dda Health Board

    lead OTHER

Principal Investigators

  • Francis WB Sanders, MB BChir PhD FRCOphth · Hywel Dda University Health Board

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-03-31
Primary Completion
2030-01-01
Completion
2030-01-01

Countries

  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06914778 on ClinicalTrials.gov